Novartis has licensed a preclinical RNA interference (RNAi) therapy from Arrowhead Pharmaceuticals targeting alpha-synuclein, a protein implicated in Parkinson's disease and other synucleinopathies. The agreement includes a $200 million upfront payment and potential milestones exceeding $2.2 billion. Arrowhead will conduct the required preclinical work while Novartis advances clinical development and commercialization. This deal underscores Novartis' renewed focus on RNAi modalities for neurodegenerative diseases amid prior setbacks in Parkinson’s drug development.